Na faasilasila e le CytoSorbents Corporation o le a auai le Kamupani i le 10th EuroELSO Congress (EuroELSO 2022) i Lonetona, UK o loʻo faia ia Me 4-6, 2022, o se tasi o konafesi tetele e lua mo tagata ECMO (extracorporeal membrane oxygenation) i le lalolagi atoa. CytoSorbents o loʻo faʻamalamalamaina le taʻiala o le "faʻaleleia o le mama malolo" e faʻaaoga ai le CytoSorb ma le ECMO e fesoasoani i le togafitia o le maʻi tigaina o le manava (ARDS) ma le faaletonu o le mama - o mafuaʻaga autu uma e lua o le oti i gasegase ICU.
O fa'amaumauga fou a le falema'i mai le 56 ma'i tigaina COVID-19 tagata mama'i ma'i fa'aletonu le manava i luga o le ola lagolago ma le ECMO ma togafitia i le CytoSorb i lalo o le FDA Emergency Use Authorization (EUA) mai le US CTC Registry o le a tu'uina atu i le Aso Tofi, Me 5, 2022, i se fa'amatalaga fa'apitoa ua fa'aulutalaina: ECMO Utilization with Adjunctive Hemoadsorption Therapy in COVID-19 Patient: An Observational Analysis from the CytoSorb Therapy in COVID-19 (CTC) Registry. O lenei suʻesuʻega fou e lagolagoina ai le taua o le vave faʻalavelave ma CytoSorb ma ECMO i le togafitia o tagata mamaʻi i le COVID-related ARDS, ma lona sao taua i le maualuga o le vaʻaia o le ola o le 52 tagata mamaʻi i se suʻesuʻega muamua o le resitala, lomia i totonu o le tusi talaaga iloiloga a tupulaga, Frontiers in Medicine, tausaga talu ai.
CytoSorbents ose lagolago platinum a le Konekeresi ma o le a talimalo foi i se faʻasalalauga faʻaaoaoga i luga ole laiga lea o le a faʻasalalau i luga o le upega tafaʻilagi a EuroELSO, faʻaigoaina "ECMO plus CytoSorb - O Tatou Faia Saʻo?" i le Aso Tofi, Me 5, 2022, mai le 12:45-1:45 PM CET i le potu St. James.
OA MEA E AVEA MAI LENEI TUSI:
- This new analysis supports the importance of early intervention with CytoSorb and ECMO in treating patients with COVID-related ARDS, and its potential role in the high observed survival of 52 patients in an earlier analysis of the registry, published in the peer-reviewed journal, Frontiers in Medicine, last year.
- CytoSorbents is a platinum sponsor of the Congress and will also host an onsite educational symposium which will be livestreamed on the EuroELSO website, entitled “ECMO plus CytoSorb – Are We Doing It Right.
- New clinical data from 56 critically ill COVID-19 patients with refractory respiratory failure on life support with ECMO and treated with CytoSorb under FDA Emergency Use Authorization (EUA) from the U.
